Rani Therapeutics Holdings Net Income
| RANI Stock | USD 1.21 0.00 0.00% |
As of the 9th of February, Rani Therapeutics holds the Variance of 28.44, risk adjusted performance of (0.1), and Coefficient Of Variation of (744.53). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Rani Therapeutics, as well as the relationship between them.
Rani Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 110.3518 | Revenue | Earnings Share (0.77) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -50.9 M | -53.5 M | |
| Net Loss | -55.1 M | -52.3 M | |
| Net Loss | -50.9 M | -53.5 M | |
| Net Loss | (1.21) | (1.27) | |
| Net Income Per E B T | 0.58 | 0.69 |
Rani | Net Income | Build AI portfolio with Rani Stock |
The Net Income trend for Rani Therapeutics Holdings offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Rani Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Rani Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Rani Therapeutics Holdings over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Rani Therapeutics financial statement analysis. It represents the amount of money remaining after all of Rani Therapeutics Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Rani Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rani Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (56.58 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Rani Net Income Regression Statistics
| Arithmetic Mean | (25,939,012) | |
| Coefficient Of Variation | (21.75) | |
| Mean Deviation | 3,158,121 | |
| Median | (26,597,000) | |
| Standard Deviation | 5,642,910 | |
| Sample Variance | 31.8T | |
| Range | 25.6M | |
| R-Value | (0.03) | |
| Mean Square Error | 33.9T | |
| R-Squared | 0 | |
| Significance | 0.89 | |
| Slope | (38,881) | |
| Total Sum of Squares | 509.5T |
Rani Net Income History
Other Fundumenentals of Rani Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Rani Therapeutics Net Income component correlations
Rani Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Rani Therapeutics is extremely important. It helps to project a fair market value of Rani Stock properly, considering its historical fundamentals such as Net Income. Since Rani Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rani Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rani Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value - what Rani Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Rani Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rani Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rani Therapeutics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Rani Therapeutics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Rani Therapeutics Holdings or generate 0.0% return on investment in Rani Therapeutics over 90 days. Rani Therapeutics is related to or competes with Innate Pharma, Milestone Pharmaceuticals, Cardiff Oncology, Cybin, Corbus Pharmaceuticals, Sangamo Therapeutics, and Elicio Therapeutics. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered ... More
Rani Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rani Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rani Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.15) | |||
| Maximum Drawdown | 26.23 | |||
| Value At Risk | (8.96) | |||
| Potential Upside | 9.28 |
Rani Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rani Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rani Therapeutics' standard deviation. In reality, there are many statistical measures that can use Rani Therapeutics historical prices to predict the future Rani Therapeutics' volatility.| Risk Adjusted Performance | (0.1) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.25) | |||
| Treynor Ratio | (0.29) |
Rani Therapeutics February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.1) | |||
| Market Risk Adjusted Performance | (0.28) | |||
| Mean Deviation | 3.74 | |||
| Coefficient Of Variation | (744.53) | |||
| Standard Deviation | 5.33 | |||
| Variance | 28.44 | |||
| Information Ratio | (0.15) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.25) | |||
| Treynor Ratio | (0.29) | |||
| Maximum Drawdown | 26.23 | |||
| Value At Risk | (8.96) | |||
| Potential Upside | 9.28 | |||
| Skewness | 0.645 | |||
| Kurtosis | 1.5 |
Rani Therapeutics Backtested Returns
Rani Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of -0.13, which implies the firm had a -0.13 % return per unit of risk over the last 3 months. Rani Therapeutics exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Rani Therapeutics' Risk Adjusted Performance of (0.1), variance of 28.44, and Coefficient Of Variation of (744.53) to confirm the risk estimate we provide. The company holds a Beta of 2.5, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rani Therapeutics will likely underperform. At this point, Rani Therapeutics has a negative expected return of -0.65%. Please make sure to check Rani Therapeutics' jensen alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Rani Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.41 |
Average predictability
Rani Therapeutics Holdings has average predictability. Overlapping area represents the amount of predictability between Rani Therapeutics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rani Therapeutics price movement. The serial correlation of 0.41 indicates that just about 41.0% of current Rani Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.41 | |
| Spearman Rank Test | 0.32 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Rani Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Rani Therapeutics Holdings reported net income of (56.58 Million). This is 116.58% lower than that of the Biotechnology sector and 180.78% lower than that of the Health Care industry. The net income for all United States stocks is 109.91% higher than that of the company.
Rani Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rani Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rani Therapeutics could also be used in its relative valuation, which is a method of valuing Rani Therapeutics by comparing valuation metrics of similar companies.Rani Therapeutics is currently under evaluation in net income category among its peers.
Rani Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Rani Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Rani Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Rani Therapeutics' value.| Shares | State Street Corp | 2025-06-30 | 62.4 K | Ubs Group Ag | 2025-06-30 | 62.1 K | King Luther Capital Management Corp | 2025-06-30 | 58 K | Janney Montgomery Scott Llc | 2025-06-30 | 55.2 K | Well Done, Llc | 2025-06-30 | 52 K | Motco | 2025-06-30 | 48.1 K | Insigneo Advisory Services Llc | 2025-06-30 | 47.5 K | Bridgeway Capital Management, Llc | 2025-06-30 | 46.5 K | Brown Advisory Holdings Inc | 2025-06-30 | 32.9 K | Armistice Capital, Llc | 2025-06-30 | 3.2 M | Vanguard Group Inc | 2025-06-30 | 799.7 K |
Rani Fundamentals
| Return On Equity | -11.88 | ||||
| Return On Asset | -0.96 | ||||
| Operating Margin | (34.18) % | ||||
| Current Valuation | 132.42 M | ||||
| Shares Outstanding | 97.55 M | ||||
| Shares Owned By Insiders | 5.73 % | ||||
| Shares Owned By Institutions | 32.29 % | ||||
| Number Of Shares Shorted | 13.81 M | ||||
| Price To Book | 23.87 X | ||||
| Price To Sales | 124.69 X | ||||
| Revenue | 1.03 M | ||||
| Gross Profit | 1.2 M | ||||
| EBITDA | (50.52 M) | ||||
| Net Income | (56.58 M) | ||||
| Cash And Equivalents | 98.17 M | ||||
| Cash Per Share | 3.97 X | ||||
| Total Debt | 29.71 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 14.02 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (35.5 M) | ||||
| Short Ratio | 7.16 X | ||||
| Earnings Per Share | (0.77) X | ||||
| Price To Earnings To Growth | 0.68 X | ||||
| Target Price | 9.25 | ||||
| Number Of Employees | 105 | ||||
| Beta | 0.43 | ||||
| Market Capitalization | 149.63 M | ||||
| Total Asset | 36.63 M | ||||
| Retained Earnings | (102.91 M) | ||||
| Working Capital | 9.85 M | ||||
| Net Asset | 36.63 M |
About Rani Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rani Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rani Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rani Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is there potential for Biotechnology market expansion? Will Rani introduce new products? Factors like these will boost the valuation of Rani Therapeutics. Anticipated expansion of Rani directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
Understanding Rani Therapeutics requires distinguishing between market price and book value, where the latter reflects Rani's accounting equity. The concept of intrinsic value - what Rani Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Rani Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Rani Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Rani Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Rani Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.